Furthermore, a retrospective single-arm study presented at the 2023 World Conference on Lung Cancer (WCLC) demonstrated that out of 20 patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations and brain metastases treated with a first-line double dose of furmonertinib, only one patient experienced grade 3 treatment-related adverse events (TRAEs) (22). Here, EGFR is linked to lung cancer.